Psychedelicnewsbreaks Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured In Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity

(MENAFN- Investor Brand Network) This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research that highlights the company's position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure, growing traction in Australia and potential operating leverage as prescription demand scales.

The commissioned report cites Optimi's regulatory licenses, existing MDMA and psilocybin manufacturing capacity, expanding commercial activity in Australia and longer-term U.S. optionality, while outlining an illustrative valuation based on discounted cash flow analysis. Diamond noted that Optimi's asset-light strategy of supplying clinical trials rather than sponsoring them may reduce development risk while positioning the company to benefit from broader regulatory adoption of psychedelic-assisted therapies.

To view the full press release, visit

About Optimi Health Corp.

Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies.

For more information, please visit

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text“Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: /Disclaimer

PsychedelicNewsWire
Austin, Texas

512.354.7000 Office
[email protected]

PsychedelicNewsWire is powered by IBN

MENAFN30102026000224011066ID1111891577